Stock Ratings / Health Care / ZVRA / options

GERN (29) NVCT (37) IRWD (63) CRMD (62) ⌘ Pro Terminal →

Zevra Therapeutics Inc. (ZVRA) Options Positioning, Max Pain & Unusual Sweeps

$10.28 -0.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.25

Zevra Therapeutics Inc. (ZVRA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $615.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZVRA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $10.28 (-0.77% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #606 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZVRA compare to GERN and NVCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (37/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, GERN (Geron Corporation) holds a E grade (29/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and NVCT (Nuvectis Pharma Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZVRA?

▼

Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $0 in revenue, $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.25 (-0.33%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZVRA)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY ZVRA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (35% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (19% of score)

FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 47 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.32-10.2% Next Q

Q2 (-2Q)

Grade D$10.16-6.2% Next Q

Q3 (-1Q)

Grade D$9.53+7.9% Next Q

Current

Grade D-$10.28-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZVRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZVRA currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.15) and Max Pain ($10.79) forces dealer call-delta covering toward $15.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZVRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZVRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ZVRA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ZVRA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZVRA)

✓Walkthrough of ZVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.29%📐 WEDGE COMPRESSION COIL

2026-11-02O $10.31H $10.36L $10.28C $10.28VOL 507.9K

RES: $10.97SUP: $9.49SMA50: $11.15SMA200: $10.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZVRA Butterfly Map → + Track ZVRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.9%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZVRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZVRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZVRA)

Health Care Rank #606 of 1016 ⚔️ GERN vs ZVRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZVRA vs. GERN, NVCT, IRWD, CRMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zevra Therapeutics Inc. (ZVRA) ranks #606 by composite RQD confidence (37/100, grade D-) and #417 by equity capitalization ($615.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with ZVRA at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZVRA ACTIVE Zevra Therapeutics Inc.	D-	37/100	7.4x	—	-32.3%	-0.77%	$615.2M	Benchmark Subject
GERN Geron Corporation	E	29/100	—	—	-20.2%	-5.47%	$607.9M	/gern-vs-zvra →
NVCT Nuvectis Pharma Inc.	D-	37/100	—	—	-35.0%	-0.48%	$605.6M	/nvct-vs-zvra →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C	63/100	24.9x	—	85.0%	-3.31%	$598.2M	/irwd-vs-zvra →
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-25.46%	$595.5M	/crmd-vs-zvra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434647

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $83.2M, operating cash flow of -$1.6M, and free cash flow of -$2.4M (+96.5% YoY). On the balance sheet, ZVRA closed FY2025 with $284.7M in total assets against $61.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$83.2M	-$1.6M	-$2.4M	$284.7M	$61.9M
FY2024 (FY)	2024-12-31	$0	-$105.5M	-$69.7M	-$69.7M	$178.1M	$59.5M
FY2023 (FY)	2023-12-31	$0	-$46.0M	-$33.5M	-$33.5M	—	—

3. ZVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZVRA compare to GERN and NVCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZVRA?

Where is ZVRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZVRA last traded at $10.28 (-0.77% on volume of 642,059 shares), positioning the stock -7.80% below its 50-day simple moving average ($11.15) and -4.37% below its 200-day simple moving average ($10.75). Across its 52-week range of $8.01 to $15.03, ZVRA sits at the 32.3% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($9.33 to $11.23).

ZVRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ZVRA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ZVRA.

Direct Sub-Reports: ZVRA RQD Cockpit ZVRA 12M Forecast ZVRA Earnings & Move ZVRA Dividends & DRIP ZVRA Insiders & 13F ZVRA Whale Options ZVRA Profit Sankey ZVRA News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZVRA — Zevra Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ZVRA scores 37 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (4 / 20): Per the Roarable RQD rating, this is the weakest pillar, reflecting ROIC of -32.3% and FCF yield of -0.4%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow to support its valuation on cash-flow grounds.
Whale 13F Flow (6 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. Investors should not read this as confirmation of institutional conviction.
Insider Conviction (7 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly. Recent news items reference insider sales, which the rating does not treat as supportive.
Macro Regime Fit (7 / 20): Per the Roarable RQD rating, beta of 1.0 and sector sensitivity score weakly. The stock's market-relative volatility is in line with the market, offering no defensive cushion in a risk-off regime.
Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.4 are the strongest pillar, though still moderate. This is the most constructive pillar in the rating.

Taken together, the rating implies a valuation that is low on earnings multiples (P/E 7.4 TTM) while the underlying operating cash engine remains negative. Upside drivers would need to come from a sustained improvement in operating returns and free cash flow; the source data does not indicate that such a turn has occurred. Investors weighing the low multiple against negative ROIC should recognize the tradeoff: earnings-based cheapness can coexist with weak cash generation. This is educational analysis, not personalized financial advice.

Business

Zevra Therapeutics Inc. (ZVRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the company profile, the company has a market capitalization of $0.6B. The source data does not describe the company's products, customers, or revenue model in detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-62.9M	$83.2M	N/A	$-2.4M	$62.4M	$61.9M
FY 2024	$0.0M	$-87.0M	$-105.5M	N/A	$-69.7M	$33.8M	$59.5M
FY 2023	$0.0M	$-49.6M	$-46.0M	N/A	$-33.5M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M across the periods shown, and operating income is negative in each. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -32.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9. Per the Roarable RQD rating, Debt/Equity is 0.4. FY 2025 shows net income of $83.2M despite negative operating income of $-62.9M, a divergence the source data does not explain.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are:

Market-wire coverage of ZVRA estimates (TradingView, marked YELLOW).
A Seeking Alpha piece on cash position relative to a rival's deal pricing (YELLOW).
A Stock Titan report of a 20,000-share sale by director Neil F. McFarlane (YELLOW).
A Stocktwits report on the stock reaching its highest levels in nearly five years (GREEN, catalyst).
A Seeking Alpha piece referencing Miplyffa and Europe as a swing factor (GREEN, catalyst).
An Investing.com report of a $224,948 stock sale by the president and CEO (YELLOW).

Risk watch items include the reported insider sales and the Seeking Alpha framing of Europe as a swing factor. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or proprietary signals are mapped. Not available in source data for supplier, customer, or sector-linkage analysis. Investors should monitor the European commercial outlook referenced in the news feed as the principal open second-order variable.

Open Questions

What drives the FY 2025 net income of $83.2M given operating income of $-62.9M, and is it recurring?
What is the company's revenue base, given reported revenue of $0.0M across all periods?
What is the status of the European market opportunity referenced in the news feed?
What is the FY 2023 cash and debt position, which is listed as N/A?
What are the terms and scale of the cash-versus-rival-deal comparison referenced in the news feed?

ZVRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zevra Therapeutics Inc. (ZVRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZVRA Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 8h ago

Zevra Therapeutics, Inc. Estimates – NASDAQ:ZVRA

TradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 11h ago

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA)

Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 14h ago

A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane.

Stock Titan report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 17h ago

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

Stocktwits report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 20h ago

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor (ZVRA)

Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 23h ago

Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.com

Investing.com Canada report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.25, Implies 146% Upside

TradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

The Manila Times report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZVRA Bull vs. Bear Conversation Board — What's Your Call at $10.28?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZVRA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.12 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ZVRA (D- • RQD 37/100) a Buy at $10.36?

Welcome to the ZVRA (Zevra Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.60 (-17.0%)

Spot @ $10.36

Pump the brakes on ZVRA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ZVRA, but look at what you are paying: 7.4x trailing P/E with tightening sector spreads. Unless Zevra Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.43 (+20.0%)

Spot @ $10.36

ZVRA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ZVRA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.36 (52-wk range $8.01 - $15.03), any beat on forward guidance forces shorts and underweight funds to chase.